[go: up one dir, main page]

PH12012501741A1 - Treatment of lupus arthritis using laquinimod - Google Patents

Treatment of lupus arthritis using laquinimod

Info

Publication number
PH12012501741A1
PH12012501741A1 PH1/2012/501741A PH12012501741A PH12012501741A1 PH 12012501741 A1 PH12012501741 A1 PH 12012501741A1 PH 12012501741 A PH12012501741 A PH 12012501741A PH 12012501741 A1 PH12012501741 A1 PH 12012501741A1
Authority
PH
Philippines
Prior art keywords
lupus arthritis
laquinimod
treatment
subject
laqumimod
Prior art date
Application number
PH1/2012/501741A
Inventor
Nora Tarcic
Asi Haviv
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501741(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PH12012501741A1 publication Critical patent/PH12012501741A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laqumimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laqumimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis This invention further provides a pharmaceutical composition comprising an amount of laqumimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.
PH1/2012/501741A 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod PH12012501741A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03
PCT/US2011/026891 WO2011109536A1 (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod

Publications (1)

Publication Number Publication Date
PH12012501741A1 true PH12012501741A1 (en) 2012-11-12

Family

ID=44531530

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501741A PH12012501741A1 (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (en)
EP (1) EP2542080B1 (en)
JP (2) JP2013521305A (en)
KR (1) KR20130036217A (en)
CN (1) CN102781239B (en)
AU (1) AU2011223702B2 (en)
BR (1) BR112012022064A2 (en)
CA (1) CA2791711A1 (en)
CL (1) CL2012002422A1 (en)
CO (1) CO6630086A2 (en)
EA (1) EA201290859A1 (en)
ES (1) ES2601819T3 (en)
MX (1) MX342001B (en)
NZ (1) NZ602512A (en)
PE (1) PE20130496A1 (en)
PH (1) PH12012501741A1 (en)
PL (1) PL2542080T3 (en)
PT (1) PT2542080T (en)
SG (2) SG183515A1 (en)
WO (1) WO2011109536A1 (en)
ZA (1) ZA201207125B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1937642T1 (en) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
PL2234485T3 (en) 2007-12-20 2014-06-30 Teva Pharma Stable laquinimod preparations
UA104005C2 (en) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-oxo-1,2-dihydro-quinoline modulators of immune function
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (en) * 2009-07-30 2016-07-29 Teva Pharma Treatment of crohn's disease with laquinimod
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
ES2558556T3 (en) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
DK2542079T3 (en) * 2010-03-03 2014-08-25 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
ES2601819T3 (en) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
EA025377B1 (en) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. DEUTERED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLOR-1-METHYL-2-OXOHINOLIN-3-CARBOXAMIDE, ITS SALT AND THEIR APPLICATION
JP2014530821A (en) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド Treatment of multiple sclerosis combining laquinimod and fingolimod
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL -1,2-DIHYDRO -4,5-DI-HYDROXY -1-METHYL -2-OXO-3-QUINOLINE CARBOXAMIDE, ITS PREPARATION AND USE
TW201350467A (en) 2012-05-08 2013-12-16 Teva Pharma N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammation with laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma Amine salts of laquinimod
HK1220125A1 (en) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
MX2015011627A (en) 2013-03-14 2016-05-16 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof.
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (en) * 1976-02-11 1977-09-09 Roussel Uclaf NEW DERIVATIVES OF 3-QUINOLEINE CARBOXYLIC ACID, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS A MEDICINAL PRODUCT
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (en) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
RS51019B (en) * 1999-10-25 2010-10-31 Active Biotech Ab. MEDICINES FOR THE TREATMENT OF MALIGNANT TUMORS
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (en) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
AU2005231467A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
WO2006029036A2 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
SI1937642T1 (en) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
EP1951674B1 (en) * 2005-10-26 2011-11-23 Merck Serono SA Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
PT2676967T (en) * 2006-02-28 2019-09-27 Biogen Ma Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2644110A1 (en) * 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
AU2007258366B2 (en) * 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
JP5468001B2 (en) * 2007-07-11 2014-04-09 メディシノバ，インコーポレーテッド Pharmaceutical composition for the treatment of progressive neurodegenerative diseases comprising ibudilast
PL2234485T3 (en) * 2007-12-20 2014-06-30 Teva Pharma Stable laquinimod preparations
UA104005C2 (en) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-oxo-1,2-dihydro-quinoline modulators of immune function
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (en) * 2009-07-30 2016-07-29 Teva Pharma Treatment of crohn's disease with laquinimod
EP2467372B1 (en) * 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
ES2601819T3 (en) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
EA025377B1 (en) * 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. DEUTERED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLOR-1-METHYL-2-OXOHINOLIN-3-CARBOXAMIDE, ITS SALT AND THEIR APPLICATION
MX2015011627A (en) * 2013-03-14 2016-05-16 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof.

Also Published As

Publication number Publication date
CO6630086A2 (en) 2013-03-01
JP2016196473A (en) 2016-11-24
US20150086549A1 (en) 2015-03-26
EP2542080A1 (en) 2013-01-09
BR112012022064A2 (en) 2015-09-08
HK1177876A1 (en) 2013-08-30
CN102781239A (en) 2012-11-14
WO2011109536A1 (en) 2011-09-09
PT2542080T (en) 2016-11-16
NZ602512A (en) 2014-07-25
CN102781239B (en) 2015-01-21
EP2542080B1 (en) 2016-08-31
CA2791711A1 (en) 2011-09-09
US20130184310A1 (en) 2013-07-18
SG10201501539SA (en) 2015-04-29
PE20130496A1 (en) 2013-05-08
EP2542080A4 (en) 2013-07-17
US20160213663A1 (en) 2016-07-28
KR20130036217A (en) 2013-04-11
PL2542080T3 (en) 2017-02-28
US20110217295A1 (en) 2011-09-08
JP2013521305A (en) 2013-06-10
MX342001B (en) 2016-09-09
AU2011223702A1 (en) 2012-10-25
SG183515A1 (en) 2012-10-30
AU2011223702B2 (en) 2016-07-14
MX2012010071A (en) 2012-10-03
ES2601819T3 (en) 2017-02-16
CL2012002422A1 (en) 2012-12-21
ZA201207125B (en) 2014-06-25
EA201290859A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MX337614B (en) Treatment of lupus nephritis using laquinimod.
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
PH12015500719A1 (en) Gdf-8-inhibitors
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MY168791A (en) Carbamate compounds and of making and using same
MX2014008021A (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain.
MX2013008192A (en) Bace-2 inhibitors for the treatment of metabolic disorders.
IN2015DN03219A (en)
MX2014001050A (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate.
MX2015010296A (en) Treatment of multiple sclerosis with laquinimod.
MX360030B (en) Methods for treating bipolar disorder.
MX2015000485A (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
TW201129361A (en) Methods for treating pain
MY195767A (en) Treatment of Androgen Deprivation Therapy Associated Symptoms
GB201115977D0 (en) Neurodevelopmental disorders
GB201312583D0 (en) Combination and composition for treating obesity
MX2016001177A (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine.
MX2014013491A (en) Methods of maintaining, treating or improving cognitive function.
IN2013MU01155A (en)